abagovomab fails placebo phase111 trial, page-30

I've been looking at the studies for abagovomab and oregovomab, monoclonal approaches to treating ovarian cancer. It seems both have failed. Abagovomab has progressed further, however it was interesting that they jumped from a Phase 1 trial that did not measure patient outcomes at all, only the immune response, straight to a Phase 3 trial, which failed.

CVac, on the other hand, has been trialled for effectiveness the whole way, Phase 1 starting with hopeless terminal cases, and miraculously saving some patients. This means we have a much more solid ground for the phase 2 and 3 trials. It reflects the very good management team, that do not waste shareholders money until there is a good chance that the trials will be successful.

So, overall good news for PRR as one potential competitor is out of the way.